| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human IFN-γ concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human IFN-γ. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human IFN-γ and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human IFN-γ, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human IFN-γ. You can calculate the concentration of Human IFN-γ in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 9.38 pg/mL |
|---|---|
| Detection Range | 15.63-1000 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human IFN-γ in samples. No significant cross-reactivity or interference between Human IFN-γ and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 9.38 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant IFN-γ standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Oleic acid restores the impaired antitumor immunity of γδ-T cells induced by palmitic acid (2025) Signal Transduction and Targeted Therapy. 10.1038/s41392-025-02295-8
Phosphoantigen-induced inside-out stabilization of butyrophilin receptor complexes drives dimerization-dependent γδ TCR activation (2025) IMMUNITY. 10.1016/j.immuni.2025.04.012
CEBPB-Regulated Gastric Cell Plasticity Promotes Liver Metastasis of Gastric Cancer (2026) Cancer Communications. 10.34133/cancomm.0016
Differential immune responses in pregnant patients recovered from COVID-19 (2021) Signal Transduction and Targeted Therapy. 10.1038/s41392-021-00703-3
Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer (2024) Journal of Extracellular Vesicles. 10.1002/jev2.12484
Targeting IGF1R Overcomes Armored and Cold Tumor Microenvironment and Boosts Immune Checkpoint Blockade in Triple-Negative Breast Cancer (2025) Advanced Science. 10.1002/advs.202501341
An Engineered Probiotic Consortium Based on Quorum-Sensing for Colorectal Cancer Immunotherapy (2025) Advanced Science. 10.1002/advs.202512744
Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia (2025) Advanced Science. 10.1002/advs.202511573
Prebiotics improve frailty status in community-dwelling older individuals in a double-blind, randomized, controlled trial (2024) JOURNAL OF CLINICAL INVESTIGATION. 10.1172/JCI176507
Sex-specific circulating unconventional neutrophils determine immunological outcome of auto-inflammatory Beh?et’s uveitis (2024) Cell Discovery. 10.1038/s41421-024-00671-2
Overcoming blood-brain barrier and chemoresistance in glioblastoma by Angiopep-2-modified NK cell-derived extracellular vesicles for targeted delivery of temozolomide (2026) JOURNAL OF NANOBIOTECHNOLOGY. 10.1186/s12951-026-04315-3
Bioengineered anti-EpCAM-guided exosome nanocarriers delivering Foxp3 agonist butyrate achieve tissue-specific immunomodulation in autoimmune Sj?gren's syndrome (2026) JOURNAL OF NANOBIOTECHNOLOGY. 10.1186/s12951-026-04373-7
Single-cell data-driven design of armed oncolytic virus and combination therapy to activate a cooperative innate-adaptive immunity against cancer (2024) MOLECULAR THERAPY. 10.1016/j.ymthe.2024.12.017
Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy (2025) Science Advances. 10.1126/sciadv.adv6445
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer (2021) Acta Pharmaceutica Sinica B. 10.1016/j.apsb.2021.07.016
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment (2023) Journal for ImmunoTherapy of Cancer. 10.1136/jitc-2023-007402
Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour‐specific immunity (2023) Clinical and Translational Medicine. 10.1002/ctm2.1255
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma (2025) CLINICAL CANCER RESEARCH. 10.1158/1078-0432.CCR-24-4338
Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation (2024) CANCER LETTERS. 10.1016/j.canlet.2024.216964
Thermosensitive hydrogel composite with si-Cx43 nanoparticles and anti-VEGF agent for synergistic treatment of diabetic retinopathy (2025) Materials Today Bio. 10.1016/j.mtbio.2025.101917
Engineering tumor-specific interferon-alpha-Nivolumab pro-immunocytokine for enhanced melanoma immunotherapy (2026) INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 10.1016/j.ijbiomac.2026.151271
Akkermansia muciniphila-derived outer membrane protein Amuc_1100 promotes acetylation of RING Finger Protein 181 promoter and mediates Autophagy Related 7 ubiquitination to activate CD8+ T cells in lung adenocarcinoma (2025) INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 10.1016/j.ijbiomac.2025.147773
Platelet-Rich Plasma-Derived Exosome-Encapsulated Hydrogels Accelerate Diabetic Wound Healing by Inhibiting Fibroblast Ferroptosis (2025) ACS Applied Materials & Interfaces. 10.1021/acsami.5c02705
Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways (2025) PHYTOMEDICINE. 10.1016/j.phymed.2025.157584
COPS6 promotes tumor progression and reduces CD8+ T cell infiltration by repressing IL-6 production to facilitate tumor immune evasion in breast cancer (2023) ACTA PHARMACOLOGICA SINICA. 10.1038/s41401-023-01085-8
